Dec 14

Artiva Named a PM360 2023 Innovative Startup

Artiva was recognized in the 2023 PM360 Innovations Issue for advancing the first allogeneic NK cell therapy to clinical trials for lupus nephritis. 

Artiva’s mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our large-scale manufacturing process is capable of producing thousands of doses of cryopreserved, infusion-ready AlloNK cells from a single umbilical cord blood unit.

Read more about this recognition here.

Recent Posts

See All

PharmaShots: Enhancing Care with NK Cell Therapy

Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots discusses: Immune reset in oncology has been observed with approved autologous CAR-T products. A study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases Artiva’s AlloNK, an allogeneic,...

BioProcess Insider: Artiva Discusses Scalable NK Cells to Treat Autoimmune Diseases

Chris Horan, Artiva’s Chief Technical Operations Officer, talks with BioProcess Insider about why decreased risk and inexpensive manufacturing might give allogeneic natural killer (NK) cell therapies the edge over chimeric antigen receptors (CAR)-T therapies. Read the article here.

BiotechTV: Checking in with Artiva CEO Fred Aslan after the Company’s $167 Million IPO

Fred Aslan describes what the funds will enable Artiva to do in the clinic, and why he believes the company’s non-modified NK cell approach is the best platform for using a cell therapy for autoimmune conditions. Watch the interview here.